Volume 30, Number 8—August 2024
Research
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance
Figure 5

Figure 5. Prevalence of complex resistance to both R and a pan-TB treatment regimen component (B, X, or both) resulting from the pan-TB compared with standard-of-care scenario in study of potential of pan-TB treatment to drive emergence of novel resistance. A) Prevalence over treatment generations; B) probability that the pan-TB scenario leads to higher prevalence of complex resistance as a proportion of all TB after 10 cohorts. Red indicates when pan-TB regimen performs better (<50% probability of higher prevalence of complex resistance) and blue when SoC regimen performs better. B, diarylquinolines; SoC, standard of care; TB, tuberculosis.
Page created: June 21, 2024
Page updated: July 20, 2024
Page reviewed: July 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.